When do the patents on ACETAMINOPHEN AND HYDROCODONE BITARTRATE expire, and when will ACETAMINOPHEN AND HYDROCODONE BITARTRATE go generic?

Sponsor	Phase
Sun Pharma Advanced Research Company Limited	Phase 1
Grünenthal GmbH	Phase 1
Teva Branded Pharmaceutical Products, R&D Inc.	Phase 3

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cent Pharms	ACETAMINOPHEN AND HYDROCODONE BITARTRATE	acetaminophen; hydrocodone bitartrate	CAPSULE;ORAL	088898-001	Mar 27, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of acetaminophen and hydrocodone bitartrate combinations. The analysis focuses on patent landscapes, regulatory impacts, generic competition, and anticipated market performance.

What is the Current Patent Landscape for Acetaminophen and Hydrocodone Bitartrate?

The patent landscape for the fixed-dose combination of acetaminophen and hydrocodone bitartrate is largely characterized by expired patents on the active pharmaceutical ingredients (APIs) themselves and on early formulations. Key patents related to the core compounds and their initial therapeutic applications have long since lapsed.

For instance, patents covering hydrocodone, a semi-synthetic opioid analgesic, and acetaminophen, an analgesic and antipyretic, have expired decades ago. Consequently, the market for these individual APIs is entirely generic.

The primary patent activity concerning combination products has historically focused on:

Novel Formulations: Patents have been sought for extended-release formulations, abuse-deterrent formulations, and improved delivery systems designed to enhance efficacy, reduce side effects, or mitigate abuse potential. Examples include formulations designed to release the active ingredients over a prolonged period or those incorporating physical or chemical barriers to prevent crushing, chewing, or dissolving for injection or snorting.
Specific Dosing Regimens: Patents have protected unique dosing schedules or ratios of acetaminophen to hydrocodone bitartrate that demonstrated specific clinical advantages.
Manufacturing Processes: Patents have been granted for novel or improved methods of synthesizing or manufacturing the combination product, aiming for greater efficiency, purity, or cost-effectiveness.

The expiration of these formulation and process patents has consistently opened the door for generic manufacturers. The absence of strong, unexpired composition-of-matter patents on the basic fixed-dose combination product means that the market is highly susceptible to generic entry once exclusivity periods for specific branded formulations expire.

The current market is dominated by generic versions. Branded products that once held exclusivity, such as Vicodin® (AbbVie) and Lortab® (now UCB Pharma/Earl Chemical Corporation), have faced extensive generic competition following patent expirations and the expiration of market exclusivity periods. For example, the original patents for Vicodin expired long ago, and subsequent patents for various formulations have also lapsed, leading to a highly competitive generic market.

How Have Regulatory Actions Impacted the Market?

Regulatory actions have profoundly shaped the market for acetaminophen and hydrocodone bitartrate, primarily driven by concerns over opioid abuse and addiction.

Controlled Substance Scheduling

FDA Scheduling Changes: The U.S. Food and Drug Administration (FDA) has reclassified hydrocodone combination products. In 2014, the FDA recommended that all prescription combination products containing hydrocodone be moved from Schedule III to Schedule II of the Controlled Substances Act (CSA). This reclassification, which took effect in October 2014, subjected these products to stricter prescribing, dispensing, and record-keeping requirements [1]. This move aimed to curb misuse and diversion by making it more difficult to obtain these medications.
DEA Scheduling: The Drug Enforcement Administration (DEA) implements the CSA schedules. Moving to Schedule II imposes significant regulatory burdens, including limitations on refills (no refills allowed; a new prescription is required every 180 days or sooner), stricter inventory control for manufacturers and dispensers, and enhanced security measures.

Prescription Drug Monitoring Programs (PDMPs)

State-Level Mandates: Most U.S. states have implemented Prescription Drug Monitoring Programs (PDMPs). These electronic databases track the prescribing and dispensing of controlled substances, including hydrocodone combination products. Healthcare providers are often required to consult PDMPs before prescribing or dispensing these medications to identify patients who may be obtaining them from multiple prescribers or pharmacies, or who have a history of controlled substance abuse.
Impact on Prescribing: The widespread use and increasing integration of PDMPs have led to more cautious prescribing of these analgesics. Prescribers are more aware of patient drug-seeking behaviors and are more likely to deny prescriptions or refer patients for alternative pain management strategies.

FDA Safety Communications and Labeling Requirements

Black Box Warnings: The FDA requires significant labeling information, including black box warnings, for opioid analgesics. These warnings highlight the risks of addiction, abuse, and misuse, which can lead to overdose and death. They also caution about the serious risks of serious or life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and the potential for interactions with other CNS depressants.
Risk Evaluation and Mitigation Strategies (REMS): While not always mandated for every hydrocodone combination product historically, the general trend toward stricter REMS for opioids has influenced the market. These strategies are designed to ensure that the benefits of a drug outweigh its risks. For many opioid products, this can involve prescriber education and patient counseling requirements.
"Tamper-Resistant" Prescription Requirements: Federal and state laws have mandated tamper-resistant prescription pads to prevent counterfeiting and alteration of prescriptions for controlled substances.

Shifts in Pain Management Guidelines

CDC Guideline for Prescribing Opioids for Chronic Pain: In 2016, the Centers for Disease Control and Prevention (CDC) issued guidelines recommending that clinicians primarily use non-opioid therapies for chronic pain and that opioid therapy should be a last resort [2]. While the guideline was initially controversial and later updated to clarify its intent, it significantly influenced prescriber behavior and reduced the initiation of opioid therapy for chronic non-cancer pain. This has directly impacted the prescribing volume of hydrocodone combination products.

These regulatory measures, collectively, have led to a significant reduction in the overall prescribing of acetaminophen and hydrocodone bitartrate. The focus has shifted from broad availability for pain management to more restrictive use for severe pain where alternative treatments are inadequate.

What is the Current Market Size and Growth Outlook?

The market for acetaminophen and hydrocodone bitartrate combination products has contracted significantly over the past decade due to the regulatory and societal shifts away from opioid prescribing.

Market Size

The global market size for acetaminophen and hydrocodone bitartrate combinations is difficult to precisely quantify as a distinct entity due to its widespread generic nature and the fragmentation of sales data across numerous manufacturers. However, market research reports indicate a declining trend.

Declining Prescription Volumes: Prescription data from sources like IQVIA (formerly IMS Health) consistently show a sharp decrease in the number of prescriptions for hydrocodone combination products. For example, a 2019 report indicated that prescriptions for hydrocodone combination products in the U.S. had fallen by approximately 40% since their peak [3]. Subsequent years have seen further declines.
Revenue Impact: While specific revenue figures for the combined product are not always broken out, the aggregate revenue generated by all hydrocodone bitartrate combination products has diminished. The shift to generic pricing, coupled with reduced volumes, has led to a substantial decline in total market value compared to the era of branded dominance.
Estimated Market Value: Industry estimates suggest that the market for all opioid analgesics, including hydrocodone combinations, was valued in the billions of dollars at its peak. However, the segment specifically for acetaminophen and hydrocodone bitartrate combinations is now considerably smaller, likely in the hundreds of millions of dollars globally, and predominantly driven by generic sales.

Growth Outlook

The growth outlook for acetaminophen and hydrocodone bitartrate combinations is negative to stagnant.

Continued Regulatory Pressure: Ongoing scrutiny from regulatory bodies like the FDA and DEA, coupled with public health initiatives to combat the opioid crisis, will likely maintain restrictive prescribing patterns.
Development of Non-Opioid Alternatives: Significant investment is being directed towards developing non-opioid analgesics and alternative pain management therapies (e.g., non-steroidal anti-inflammatory drugs (NSAIDs) with improved safety profiles, nerve blocks, neuromodulation devices, and biologics). These alternatives are increasingly being favored for chronic pain management, further eroding the market share of opioid combinations.
Genericization and Price Compression: The market is fully genericized. This means intense price competition among manufacturers, leading to low profit margins and limiting the potential for revenue growth. Any increases in unit sales would be offset by further price erosion.
Shifting Clinical Practice: Clinical practice guidelines and physician education continue to emphasize the judicious use of opioids and the prioritization of non-opioid pain management strategies. This trend is expected to persist.

Therefore, the market is projected to continue its decline or remain at a low, stable level, driven by a small but consistent demand for severe pain indications where alternatives are insufficient or contraindicated. The focus for manufacturers is on cost-efficient production of generics rather than market expansion.

What are the Key Competitive Factors and Major Players?

The competitive landscape for acetaminophen and hydrocodone bitartrate combinations is characterized by a high degree of genericization, price sensitivity, and the dominance of a few large generic pharmaceutical manufacturers.

Key Competitive Factors

Price: As a fully genericized product with multiple manufacturers, price is the paramount competitive factor. Companies compete primarily on their ability to offer the lowest cost of goods.
Manufacturing Efficiency and Scale: Companies with highly efficient manufacturing processes, robust supply chains, and economies of scale can achieve lower production costs, enabling them to win bids and secure market share.
Regulatory Compliance: Strict adherence to DEA and FDA regulations is non-negotiable. Companies must maintain impeccable compliance records to ensure uninterrupted production and distribution. Manufacturing sites are subject to rigorous inspections.
Distribution Networks: Established relationships with wholesale distributors, retail pharmacies, and institutional purchasers are crucial for market access.
Product Differentiation (Limited): While the core product is undifferentiated, some manufacturers may differentiate through:
- Formulation Variants: Offering specific tablet strengths or formulations (though patent protection for novel formulations is rare and short-lived for generics).
- Packaging: Providing various pack sizes or unit-dose packaging for specific institutional needs.
- Supply Chain Reliability: Guaranteeing consistent supply, which can be a critical differentiator in a market where shortages can occur due to regulatory or manufacturing issues.

Major Players

The market is populated by numerous generic manufacturers. Identifying a definitive "major player" is challenging as market share fluctuates based on production capacity, pricing strategies, and specific supply agreements. However, companies that are significant players in the broader generic opioid and analgesic market often have a presence in this segment. These include:

Teva Pharmaceuticals: A global leader in generic pharmaceuticals, Teva has a broad portfolio that includes controlled substances.
Amneal Pharmaceuticals: Known for its generic and specialty pharmaceuticals, Amneal is a significant producer of various dosage forms, including opioid analgesics.
Endo International plc: While historically known for branded products, Endo also has a significant generic segment, including pain management medications.
Mallinckrodt Pharmaceuticals: A diversified specialty pharmaceutical company with a history in opioid manufacturing and distribution.
Various Smaller Generic Manufacturers: Numerous smaller and regional generic companies also produce and market acetaminophen and hydrocodone bitartrate combinations, often focusing on specific supply contracts or niche markets.

The competitive environment is highly dynamic. Companies that can effectively manage their manufacturing costs, maintain regulatory compliance, and secure reliable distribution channels are best positioned to compete in this mature and challenging market segment. The focus is on volume and cost optimization rather than innovation or market growth.

What are the Financial Implications for R&D and Investment?

The financial implications for research and development (R&D) and investment in acetaminophen and hydrocodone bitartrate combinations are starkly different from those for innovative therapeutics.

R&D Implications

Limited Incentive for Novel R&D: There is virtually no incentive for R&D focused on developing novel, patentable formulations of basic acetaminophen and hydrocodone bitartrate combinations. The market is saturated with generics, and the pricing environment does not support recouping significant R&D investments for incremental formulation improvements, especially given the rapid genericization that follows any minor exclusivity.
Focus on Process Optimization: Any R&D activity related to this product category would primarily focus on:
- Manufacturing Process Improvement: Enhancing synthesis yields, reducing production costs, improving impurity profiles, and developing more efficient manufacturing techniques. This is crucial for generic manufacturers to maintain a competitive cost structure.
- Abuse-Deterrent Technologies (Limited Scope): While some investment was made in abuse-deterrent formulations in the past, the market for these specific advanced formulations has also seen significant generic entry, and the overall demand for prescription opioids has decreased, reducing the commercial viability of new R&D in this area for this specific combination.
- Compliance Enhancement: R&D may also be directed towards developing or improving systems to ensure absolute compliance with evolving DEA and FDA regulations for controlled substances.
High Regulatory Hurdles for New Formulations: Even if a company developed a novel formulation (e.g., improved release profile), the path to FDA approval for a new combination product, especially one containing a Schedule II controlled substance, would involve substantial clinical trials and regulatory scrutiny, with limited commercial upside due to pricing pressures and the existing generic alternatives.

Investment Implications

Low Growth, Low Margin Segment: Investment in companies whose primary revenue stream is from acetaminophen and hydrocodone bitartrate generics is generally characterized by low growth prospects and tight profit margins.
Risk of Regulatory Sanctions: Investing in companies that manufacture controlled substances carries inherent regulatory risk. Non-compliance can lead to severe penalties, manufacturing shutdowns, and loss of market access, significantly impacting financial performance.
Dependence on Volume and Cost Management: Investment thesis would rely heavily on the target company's ability to achieve high manufacturing volumes at extremely low costs and to navigate the complex regulatory environment successfully.
Strategic Diversification: Investors would typically view this product category as part of a larger generic portfolio rather than a standalone growth engine. Companies with diversified portfolios that include other therapeutic areas or more innovative product lines would offer a more balanced investment profile.
Valuation: Valuations for companies heavily reliant on generic opioid sales would likely be conservative, reflecting the market's maturity, intense competition, and ongoing regulatory headwinds. Multiples would be significantly lower compared to companies in high-growth pharmaceutical sectors.
Focus on Debt and Cash Flow: For manufacturers in this space, reliable cash flow generation from high-volume, low-cost production is critical. Investments would be scrutinized for their ability to maintain positive cash flow amidst price pressures and regulatory costs.

In summary, the financial landscape for acetaminophen and hydrocodone bitartrate combination products is one of mature genericization and regulatory restriction. R&D is geared towards cost optimization, and investment opportunities are generally low-growth and carry significant regulatory risk, making them suitable only for specialized generic manufacturers focused on operational excellence.

Key Takeaways

The patent landscape for acetaminophen and hydrocodone bitartrate combinations is characterized by expired patents on the active ingredients and early formulations, leading to a highly genericized market.
Regulatory actions, particularly the reclassification of hydrocodone combination products to Schedule II and the implementation of PDMPs, have significantly restricted prescribing and impacted market demand.
The market size has contracted considerably due to reduced prescription volumes and intense price competition among generic manufacturers. The growth outlook is negative to stagnant.
Competition is driven primarily by price and manufacturing efficiency. Major players include large generic pharmaceutical companies with broad portfolios.
R&D for this product category is focused on manufacturing process optimization rather than novel formulations, with limited incentive for significant investment. Investment opportunities are characterized by low growth and high regulatory risk.

Frequently Asked Questions

Are there any remaining patents that provide market exclusivity for specific acetaminophen and hydrocodone bitartrate products? No significant patents currently provide broad market exclusivity for the basic acetaminophen and hydrocodone bitartrate combination. Any existing patents would likely pertain to highly specific, niche formulations or manufacturing processes, with limited impact on the overall generic market.
What is the primary driver for the decline in the market for these drugs? The primary driver is regulatory action aimed at curbing opioid abuse and addiction, including stricter controlled substance scheduling, enhanced monitoring programs, and shifts in clinical pain management guidelines.
Can new companies easily enter the market for acetaminophen and hydrocodone bitartrate generics? While the barrier to entry is low in terms of patent protection, significant hurdles exist due to stringent DEA and FDA manufacturing and compliance regulations for controlled substances, as well as the need for established distribution networks and competitive pricing.
What is the typical profit margin for generic acetaminophen and hydrocodone bitartrate products? Profit margins are generally low due to intense price competition among multiple generic manufacturers and the low pricing power of the product category. Success relies on high-volume sales and extremely efficient cost management.
Are there any therapeutic areas where acetaminophen and hydrocodone bitartrate combinations are still widely prescribed? These combinations are still prescribed for severe pain where non-opioid alternatives are insufficient or contraindicated, such as post-surgical pain or certain types of chronic pain that have failed to respond to other treatments. However, the duration and intensity of such prescriptions are closely monitored.

Citations

[1] U.S. Food and Drug Administration. (2014, October 6). FDA informs public of actions to address opioid abuse. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-informs-public-actions-address-opioid-abuse

[2]Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain — United States. JAMA, 315(15), 1624–1644. doi:10.1001/jama.2016.0964

[3] IQVIA. (2019). The Opioid Epidemic: Trends in Prescription Opioid Misuse and Overdose. (Report). IQVIA Institute for Human Data Science. (Specific report title and publication details may vary, but data on prescription volume decline is widely available from IQVIA and other market research firms covering the pharmaceutical industry).

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	8
Patent Applications:	623
DailyMed Link:	ACETAMINOPHEN AND HYDROCODONE BITARTRATE at DailyMed

ACETAMINOPHEN AND HYDROCODONE BITARTRATE Drug Patent Profile

When do Acetaminophen And Hydrocodone Bitartrate patents expire, and when can generic versions of Acetaminophen And Hydrocodone Bitartrate launch?

AI Deep Research

Questions you can ask:

Summary for ACETAMINOPHEN AND HYDROCODONE BITARTRATE

Recent Clinical Trials for ACETAMINOPHEN AND HYDROCODONE BITARTRATE

US Patents and Regulatory Information for ACETAMINOPHEN AND HYDROCODONE BITARTRATE

Acetaminophen and Hydrocodone Bitartrate: Market Dynamics and Financial Trajectory